Clinical Trials Directory

Trials / Completed

CompletedNCT05621187

Post Market Clinical Follow-up Study for the Pamira ICD Lead Family

BIO|MASTER.Pamira Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
221 (actual)
Sponsor
Biotronik SE & Co. KG · Industry
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

Confirm clinical safety and performance of the Pamira lead to support the regulatory post market strategy in Europe and other regions and validating promotional claims by * demonstrating clinical safety * evaluating performance based on sensing and pacing assessment * collecting additional data of interest to assess other aspects such as the handling and usability

Conditions

Interventions

TypeNameDescription
DEVICEPamira ICD lead familyImplantation, measurements and follow-up schedule

Timeline

Start date
2022-11-30
Primary completion
2025-01-20
Completion
2025-01-20
First posted
2022-11-17
Last updated
2025-02-26

Locations

23 sites across 8 countries: Australia, Austria, Belgium, Germany, Hungary, Israel, Latvia, Slovakia

Source: ClinicalTrials.gov record NCT05621187. Inclusion in this directory is not an endorsement.

Post Market Clinical Follow-up Study for the Pamira ICD Lead Family (NCT05621187) · Clinical Trials Directory